Tesamorelin VS MK677

Important Regulatory Notice: Tesamorelin (Egrifta®) is an FDA-approved prescription drug indicated solely for the reduction of excess abdominal fat in HIV-infected individuals with lipodystrophy. It is not sold by BehemothLabz and is not available without a prescription. MK-677 is a research compound not approved for any use, supplied by BehemothLabz strictly for laboratory research. This article is a mechanistic comparison for research context only.

Quick Answer: What is the key mechanistic difference? Tesamorelin is a synthetic GHRH analogue that directly activates GHRH receptors on pituitary somatotrophs. MK-677 is an orally active GHSR-1a (ghrelin receptor) agonist. Both elevate GH/IGF-1 in preclinical models via different upstream mechanisms. Neither is approved for general research or veterinary use.

Researchers looking to buy MK-677 for laboratory investigation can source it as a research-grade compound at BehemothLabz. All products are independently third-party tested, with COA available per batch. Sold strictly for laboratory research only.

Disclaimer: MK-677 (Ibutamoren) is a research compound not approved by the U.S. FDA for any use. Strictly for laboratory research only.

Compound Overview

Tesamorelin: A 44-amino acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). FDA-approved in 2010 for the reduction of excess abdominal fat in HIV-infected individuals with lipodystrophy (Falutz et al. 2010, PMID 20101189). Not approved for any other use. Prescription only.

MK-677 (Ibutamoren): A synthetic non-peptide small molecule GHSR-1a agonist. Not FDA-approved for any use. Supplied by BehemothLabz strictly for laboratory research.

Mechanistic Comparison in Preclinical Models

Primary receptor target: Tesamorelin → GHRH receptor on pituitary somatotrophs. MK-677 → GHSR-1a (ghrelin receptor) in the hypothalamus and pituitary.

Downstream signalling: Both activate the GH/IGF-1 axis and stimulate pulsatile GH release in preclinical models. The mechanism of upstream activation differs.

Route in preclinical data: Tesamorelin — subcutaneous injection (peptide, not orally bioavailable). MK-677 — orally active non-peptide (sulfonamide backbone).

Half-life: Tesamorelin — approximately 26 minutes (short-acting; GH pulse pattern preserved). MK-677 — approximately 24 hours (once-daily dosing in preclinical study designs).

IGF-1 elevation: Both are documented in published investigational literature. Chapman et al. 1996 (MK-677): 97% GH elevation, IGF-1 raised to young-adult range. Falutz et al. 2010 (Tesamorelin): visceral fat reduction with maintained IGF-1 elevation.

WADA classification: Both are classified under WADA S2.2.4 — Growth Hormone-Releasing Hormones and their mimetics.

Appetite stimulation: MK-677 — consistent appetite stimulation documented across preclinical studies (ghrelin mimicry). Tesamorelin — not documented as a primary adverse signal in published literature.

Regulatory status: Tesamorelin: FDA-approved Rx drug (HIV lipodystrophy indication only). MK-677: no approval, research compound only.

Risks and Limitations of MK-677 / Tesamorelin Comparative Research

Mandatory reading before working with this compound in any laboratory setting.

Tesamorelin is Prescription-Only

Tesamorelin is an FDA-approved prescription drug. Any experimental design involving tesamorelin requires appropriate institutional and DEA compliance for Schedule-adjacent compounds.

Buy Tesamorelin

MK-677 Cardiovascular Signal

The Adunsky et al. 2011 investigational study documented congestive heart failure signals leading to early study termination. Any MK-677 research design must include cardiovascular monitoring.

Buy MK-677

MK-677 Appetite Confounders

Appetite stimulation (ghrelin mimicry) must be controlled for in any MK-677 study where body weight or food intake is an outcome variable.

Storage

MK-677: room temperature, dry, sealed, away from light. Tesamorelin: per pharmaceutical prescribing information.

Data Limitations

Mechanistic comparison is based on published investigational and clinical literature. No direct head-to-head preclinical study comparing tesamorelin and MK-677 has been published. 

Conclusion

Tesamorelin and MK-677 both activate the GH/IGF-1 axis in preclinical and investigational research contexts but via fundamentally different upstream mechanisms: GHRH receptor activation (tesamorelin) vs GHSR-1a agonism (MK-677). Tesamorelin is an FDA-approved prescription drug with a narrow approved indication; MK-677 is an orally active research compound with no approved use. Both are classified under WADA S2.2.4. Researchers designing studies involving GH axis parameters must account for the different mechanistic pathways, route differences, and adverse signal profiles documented for each compound.

MK-677 is available for sale at BehemothLabz for licensed laboratory research use only. Each batch is independently third-party tested, and a Certificate of Analysis (COA) is available per batch. Not for any other use.

FAQs

What is the mechanistic difference between tesamorelin and MK-677?

Tesamorelin activates GHRH receptors on pituitary somatotrophs (a GHRH analogue). MK-677 activates GHSR-1a (ghrelin receptor) in the hypothalamus and pituitary (a non-peptide small molecule). Both elevate GH and IGF-1 in preclinical models via different upstream mechanisms.

Is Tesamorelin FDA-approved?

Yes. Tesamorelin (Egrifta®) is FDA-approved as a prescription drug for the reduction of excess abdominal fat in HIV-infected individuals with lipodystrophy. It is not sold by BehemothLabz and requires a valid prescription.

What is their WADA classification?

Both tesamorelin and MK-677 are classified under WADA S2.2.4 — Growth Hormone-Releasing Hormones and their mimetics.

Can MK-677 be used as a research substitute for tesamorelin?

No. These compounds have different mechanisms, regulatory statuses, and adverse signal profiles. They cannot be substituted for each other in any context.

Where can I buy MK-677 for research?

BehemothLabz offers MK-677 for sale for laboratory research purposes only. Each batch is independently third-party tested, with a COA available per batch.

ATTENTION — BehemothLabz Research Compound Notice

All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for any other use. Contact support@behemothlabz.com with any concerns.

References

•       Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311–322. https://pubmed.ncbi.nlm.nih.gov/20101189/